Adjuvant radiotherapy for endometrial cancer - a comparative review of radiotherapy technique with acute toxicity

Objectives: The addition of pelvic radiotherapy to brachytherapy (EBRT-BT) in early-stage endometrial cancer is controversial and may cause unnecessary toxicity. The incidence of acute toxicity of EBRT-BT will have an impact on clinical decision and patient compliance but is currently poorly understood. This study compares the acute toxicities of EBRT-BT versus BT alone. Materials and Methods: Seventy-nine patients with FIGO Stage IA-II endometrial cancer who underwent adjuvant radiotherapy, (EBRT-BT or BT alone) from 2001 to 2011 were included in the study. Medical records of these patients were reviewed retrospectively and toxicity graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Patients were followed up for at least three months post-treatment to assess resolution of toxicity. Results: The mean age of the study group was 60.6 years. Median follow-up was four years. Forty pa-tients received EBRT-BT. There was a 37% increase in Grade 1-3 diarrhea with the addition of pelvic radiotherapy (OR 18.67, p < 0.0005) and a 34% increase in lethargy (p < 0.0005). There was also an increased occurrence of genitourinary and skin toxicities. Two patients in the EBRT-BT group required hospitalisation for severe diarrhea and three patients were unable to complete the treatment. All acute toxicities had resolved by three months post treatment. Conclusion: EBRT-BT causes significantly more acute toxicities compared to BT alone. Patients should be informed of this during counselling.

Endometrial cancer; Brachytherapy; Radiotherapy; Toxicity.

[1] Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J. J., Wárlám- Rodenhuis C.C., et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma”. Lancet, 2000, 355, 1404.

[2] Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al.: “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744.

[3] Kucera H., Vavra N., Weghaupt K.: “Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors”. Gynecol. Oncol., 1990, 38, 99.

[4] Lee C.M., Szabo A., Shrieve D.C., Macdonald O.K., Tward J.D., Skidmore T.B. et al.: “Descriptive nomograms of adjuvant radio-therapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: a surveillance, epidemiology and end results population study”. Cancer, 2007, 110, 2092.

[5] Small W. Jr., Erickson B., Kwakwa F.: “An American Brachytherapy Society survey regarding practice patterns of postoperative irradia-tion for endometrial cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63, 1502.

[6] Pitson G., Colgan T., Levin W., Lockwood G., Manchul L., Milosevic M., et al.: “Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 53, 862.

[7] Aalders J., Abeler V., Kolstad P., Onsrud M.: “Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients”. Obstet. Gynecol., 1980, 56, 419.

[8] Sorbe B., Horvath G., Andersson H., Boman K., Lundgren C., Pettersson B.: “External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endome-trial carcinoma – A prospective randomized study”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82, 1249.

[9] Huscher A., Bignardi M., Magri E., Vitali E., Pasinetti N., Costa L et al.: “Determinants of small bowel toxicity in postoperative pelvic irradiation for gynaecological malignancies”. Anticancer Res., 2009, 29, 4821.

[10] Chitapanarux I.: “Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients”. Radiat. Oncol., 2010, 5, 31.

[11] Peeters S.T., Heemsbergen W.D., van Putten W.L., Slot A., Tabak H., Mens J.W., et al.: “Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 61, 1019.

[12] Salama J.K., Mundt A.J., Roeske J., Mehta N.: “Preliminary out-come and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 1170.

[13] Hazewinkel M.H., Sprangers M.A., van der Velden J., van der Vaart C. H., Stalpers L.J., Burger M.P., et al.: “Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-sectional matched cohort study”. Gynecol. Oncol., 2010, 117, 281.

[14] Forrest J.L., Ackerman I., Barbera L., Barnes E.A., Davidson M., Kiss A., et al.: “Patient outcome study of concurrent chemoradia-tion, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix”. Int. J. Gynecol. Cancer, 2010, 20, 1074. .

[15] Nout R.A., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L. C., van der SteenBanasik E.M., et al.: “Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: first Results of the Randomized PORTEC-2 Trial”. J. Clin. Oncol., 2009, 27, 3547.

[16] Sharma C., Deutsch I., Lewin S.N., Burke W.M., Qiao Y., Sun X., et al.: “Lymphadenectomy influences the utilization of adjuvant radi-ation treatment for endometrial cancer”. Am. J. Obstet. Gynecol., 2011, 205, 562.e1.

[17] May K., Bryant A., Dickinson H.O., Kehoe S., Morrison J.: “Lymphadenectomy for the management of endometrial cancer”. Cochrane Database Syst. Rev., 2010, 1, CD007585.

[18] ASTEC Study Group, Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K.: “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study”. Lancet, 2009, 373, 125.

[19] Benedetti Panici P., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G., et al.: “Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial”. J. Natl. Cancer Inst., 2008, 100, 1707.

[20] Laurentius T., Altendorf-Hofmann A., Camara O., Runnebaum I.B., Wendt T.G.: “Impact of age on morbidity and outcome of concur-rent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery”. J. Cancer Res. Clin. Oncol., 2011, 137, 481.

[21] Kunos C., Tian C., Waggoner S., Rose P.G., Lanciano R.: “Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study”. Int. J. Gynecol. Cancer, 2009, 19, 1258.

[22] Ferrigno R., Santos A., Martins L.C., Weltman E., Chen M.J., Sakuraba R. et al.: “Comparison of conformal and intensity modulated radiation therapy techniques for treatment of pelvic tumors. Analysis of acute toxicity”. Radiat. Oncol., 2010, 5, 117.

[23] Cozzarini C., Fiorino C., Di Muzio N., Alongi F., Broggi S., Cattaneo M. et al.: “Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer”. Radiother. Oncol., 2007, 84, 164.

[24] Macdonald D.M., Lin L.L., Biehl K., Mutic S., Nantz R., Grigsby

P. W.: “Combined intensity-modulated radiation therapy and brachytherapy in the treatment of cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 618.

[25] Robertson J.M., Söhn M., Yan D.: “Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model”. Int. J. Radiat. Oncol. Biol. Phys., 2010, 77, 66.

[26] Fiorino C., Alongi F., Perna L., Broggi S., Cattaneo G.M., Cozzarini C., et al.: “Dose-volume relationships for acute bowel toxicity in pa-tients treated with pelvic nodal irradiation for prostate cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 29.

[27] Katsanos K.H., Briasoulis E., Tsekeris P., Batistatou A., Bai M., Tolis C., et al.: “Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis”. J. Exp. Clin. Cancer Res., 2010, 29, 68.

[28] Chitapanarux I., Chitapanarux T., Traisathit P., Kudumpee S., Tharavichitkul E., Lorvidhaya V.: “Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients”. Radiat. Oncol., 2010, 5, 31.